Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced it has secured a $53 million first close in Series C financing. The funds will be used to support development activities for the Katana Thrombectomy System and the NavIQ quantification software, completion of enrollment in the QUADRA-PE clinical trial and regulatory submissions. The round was led by Qatar Investment Authority (QIA) with participation by current investors. Part of the funds will be used to set up a joint venture in Qatar.